On the one hand, studies have shown that OTUD6B-AS1 can inhibit tumor growth in kidney cancer, thyroid cancer, and colorectal cancer, while promote tumor growth in hepatocellular carcinoma [42–45]. Here, OTUD6B is linked to neoplasm.